iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Dec 19, 2019

Keywords

ClinConnect Summary

This clinical trial is examining a new device called the iGlucose® Remote Patient Monitoring Device. The goal of the study is to see if using this device, which helps track blood sugar levels more easily, can improve health outcomes for women with gestational diabetes or type 2 diabetes during pregnancy. By automating the way blood sugar data is collected, the researchers hope to help women better manage their diabetes and meet the recommended number of blood sugar checks.

To participate in this trial, women must be at least 18 years old and diagnosed with gestational diabetes or type 2 diabetes before reaching 30.6 weeks of pregnancy. Participants should be carrying a single, healthy baby and be able to give their consent to join the study. Unfortunately, women with type 1 diabetes or certain fetal abnormalities cannot take part. If you join the trial, you can expect to use the iGlucose® device, which may make monitoring your blood sugar levels simpler and more efficient. This study is currently looking for new volunteers, so if you or someone you know is eligible, it could be a great opportunity to contribute to important research while managing diabetes during pregnancy.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• • All patients \>/= women 18 years of age with gestational diabetes or type 2 diabetes during pregnancy and identified by the research team and consented before 30.6 weeks.
• • Non-anomalous singletons
• • Ability to provide informed consent
• • Exclusion Criteria
• • Patients with Type 1 diabetes
• • Patients with fetal major congenital abnormalities
• • Patients identified/referred after 30.6 weeks